A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms NEPTUNE
- Sponsors AstraZeneca; AstraZeneca AB
Most Recent Events
- 16 Jan 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 13 Feb 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
- 01 Apr 2023 Results of prespecified exploratory analysis (extended cohort enrolled in China) assessing efficacy and safety of durvalumab plus tremelimumab in patients with metastatic non-small-cell lung cancer, published in the Lung Cancer.